- In March 2024, Zoetis Inc., a global leader in animal health, introduced SyncSure, a next-generation hormone-based fertility synchronization solution for dairy cattle in North America and Europe. Designed to improve conception rates and streamline breeding cycles, SyncSure combines proven hormonal protocols with data-driven monitoring tools, highlighting Zoetis’ continued investment in enhancing reproductive efficiency and livestock productivity through science-based innovations
- In February 2024, Boehringer Ingelheim expanded its veterinary hormone production facility in Germany to meet rising global demand for animal reproductive and metabolic therapies. The expansion includes state-of-the-art manufacturing capabilities for peptide-based hormones and aligns with the company’s strategic objective to increase its footprint in the livestock fertility market, particularly in Asia-Pacific and Latin America
- In January 2024, Ceva Santé Animale launched ReproOne, a comprehensive hormonal fertility management program in India, targeting small and medium-scale dairy farmers. The initiative aims to boost milk production through improved calving rates and educate rural veterinarians on proper hormone usage. This development underscores Ceva’s focus on tailored solutions for emerging markets and its commitment to sustainable animal health practices
- In November 2023, Elanco Animal Health collaborated with a leading agri-tech startup to integrate hormone therapy protocols with precision livestock farming tools in Brazil. The pilot program leverages real-time biosensor data to optimize hormone administration in beef cattle, aiming to reduce hormone waste and improve outcomes. This marks a shift toward digital-hormonal convergence in the veterinary space, enhancing productivity while promoting responsible usage
- In October 2023, Virbac introduced a new formulation of long-acting progesterone implants for swine breeding programs across Southeast Asia. The product offers extended hormonal coverage with fewer applications, reducing stress on animals and labor for farmers. This advancement reflects Virbac’s commitment to developing efficient, welfare-oriented hormone therapies tailored to regional production needs
